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Abstract 
Prenatal development is a critical period for programming of neurological disease. Preeclampsia, a 
pregnancy complication involving oxidative stress in the placenta, has been associated with long-term 
health implications for the child, including an increased risk of developing schizophrenia and autism 
spectrum disorders in later life. To investigate if molecules released by the placenta may be important 
mediators in foetal programming of the brain, we analysed if placental tissue delivered from patients 
with preeclampsia secreted molecules that could affect cortical cells in culture. Application of culture 
medium conditioned by preeclamptic placentae to mixed cortical cultures caused changes in neurons 
and astrocytes that were related to key changes observed in brains of patients with schizophrenia and 
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autism, including effects on dendrite lengths, astrocyte number as well as on levels of glutamate and 
GABA receptors. Treatment of the placental explants with an antioxidant prevented neuronal 
abnormalities. Furthermore, we identified that bidirectional communication between neurons and 
astrocytes, potentially via glutamate, is required to produce the effects of preeclamptic placenta 
medium on cortical cells. Analysis of possible signalling molecules in the placenta-conditioned 
medium showed that the secretion profile of extracellular microRNAs, small post-transcriptional 
regulators, was altered in preeclampsia and partially rescued by antioxidant treatment of the placental 
explants. Predicted targets of these differentially abundant microRNAs were linked to 
neurodevelopment and the placenta. The presented study provides further evidence that the diseased 
placenta may release factors that damage cortical cells and suggests the possibility of targeted 
antioxidant treatment of the placenta to prevent neurodevelopmental disorders. 
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Abbreviations: GABA, gamma-aminobutyric acid; NMDA, N-methyl-D-aspartate; NP, nanoparticles; 
PE, preeclampsia; TH+, tyrosine hydroxylase-positive 
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Introduction 
Prenatal development represents a critical period of neurodevelopment and is of importance to the 
long-term health of the offspring (1). The placenta is thought to play a key role in brain development 
and in foetal programming of neurological disease (2-4) but the mechanism is still unclear. 
Preeclampsia, affecting 2-8% of pregnancies worldwide (5), is characterized by chronic gestational 
hypertension and significant proteinuria, along with maternal organ dysfunction or intrauterine growth 
restriction (6). Not only does it increase maternal and foetal mortality, preeclampsia has long-term 
health implications for both mother and child, including an increased risk of schizophrenia (7-9) and 
autism spectrum disorders (10, 11) in the offspring. In fact, according to a recent clinical meta-
analysis (11), offspring exposed to preeclampsia had a 32% higher risk of developing autism spectrum 
disorders compared to offspring from pregnancies not complicated by preeclampsia. While aspirin is 
recommended as prophylaxis specifically in high-risk women (12, 13), the most effective treatment is 
delivery of foetus and placenta (5), pointing towards a key role of the placenta in the disease. In fact, 
poor placentation, specifically abnormal remodelling of spiral arteries, thereby creating an ischemic 
placenta, has been identified as an underlying cause of preeclampsia (14). Studies analysing human 
placental tissue point towards a role of placental oxidative stress (15-22) and mitochondrial 
dysfunction (23-27) in preeclampsia. 
We have previously observed schizophrenia-related neurodevelopmental abnormalities in adolescent 
rats exposed to gestational hypoxia, which were prevented when oxidative stress in the placenta was 
reduced (28). Secretions from the hypoxic placenta and in the foetal blood, applied to cortical 
neurons, altered neuronal characteristics in a similar manner to the changes observed in the offspring 
brains, suggesting that factors released from the placenta may play a key role in mediating the effects 
of gestational hypoxia on neurodevelopment (28, 29). Using placental tissue from patients with 
preeclampsia, we further explore the hypothesis that secretions from the diseased placenta can cause 
abnormalities in cortical neurons and astrocytes.   
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Results 
Conditioned medium from preeclamptic placentae affects dendrite lengths, glutamate receptor 
and GABA receptor levels 
Mixed cortical cultures were exposed to culture medium conditioned by preeclamptic placental 
explants (PE medium) or by non-diseased explants (healthy medium) (Figure 1; Supplementary 
Figure S1). PE medium applied to cortical cultures significantly reduced mean dendrite length (Figure 
1a) as well as process lengths of tyrosine hydroxylase-positive (TH+) neurons (Figure 1b) compared to 
healthy medium. Levels of glutamate receptor subunit GluN1 were significantly reduced following 
exposure to PE medium (Figure 1c). In contrast, glutamate receptor subunit GluN3α intensity was not 
altered (Figure 1d). Cortical cultures exposed to PE medium showed an increase in the levels of 
GABA receptor subunit GABA Aα1 (Figure 1e) while levels of subunit GABA B1 were unchanged 
(Figure 1f). Astrocyte numbers (Figure 1g) and process lengths (Figure 1h) were significantly 
increased in cortical cultures following exposure to PE medium. 
Next, we queried if oxidative stress within the preeclamptic placenta could contribute to the effects of 
conditioned medium on cortical cultures. A previous study indicated that antioxidant MitoQ, as a 
nanoparticle formulation (MitoQ-NP), was able to enter placental cells, reduce oxidative stress and 
prevent damaging placental secretions in vivo (28). We tested here if MitoQ-NP application could also 
prevent damaging secretions when applied to preeclamptic placental tissue ex vivo. PE placentae were 
exposed to MitoQ-NPs at the start of the ex vivo period. As a control, blank nanoparticles (blank-NPs) 
without MitoQ were used. Treatment of placental explants with MitoQ-NPs did not affect dendrite 
lengths of neurons exposed to healthy medium (Figure 1a). In contrast, MitoQ-NP treatment rescued 
the effects of PE medium on dendrite lengths (Figure 1a). Furthermore, application of MitoQ-NPs to 
preeclamptic placental tissue rescued the reduction in TH+ process lengths (Figure 1b), GluN1 levels 
(Figure 1c) and GABA Aα1 levels (Figure 1e) following exposure to PE medium. In addition, MitoQ-
NPs partially reduced the effect of PE medium on astrocyte processes lengths so that there was no 
significant difference between cultures exposed to healthy or PE medium, following MitoQ-NP 
treatment (Figure 1h). No effect of MitoQ-NP treatment was observed on levels of GluN3α (Figure 
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1d) or GABA B1 (Figure 1f) or on astrocyte cell count (Figure 1g) in cultures exposed to PE medium. 
Application of blank NPs to placental explants did not affect dendrite lengths, TH+ process lengths, 
GluN1 levels, GluN3α levels, GABA Aα1 levels or GABA B1 levels of cortical cultures exposed to 
PE medium (Figure 1a-f). 
Taken together, culture medium conditioned by preeclamptic placental tissue significantly altered 
neuronal process lengths, glutamate and GABA subunit levels as well as astrocyte numbers and 
process lengths. Treatment of the placental tissue with MitoQ-NPs successfully prevented several of 
these changes. 
 
Glutamate receptor inhibition prevented effects of PE medium on neuronal process lengths 
We previously identified glutamate as one of the factors that may mediate adverse effects of culture 
medium conditioned by a model placental barrier, exposed to hypoxia, on cortical cultures (29). We 
therefore investigated if glutamate could also play a role in mediating the damaging effects of PE 
medium on neurons. Cortical cultures were pre-treated with MK801, a non-competitive antagonist of 
NMDA receptors, before incubation with healthy medium or PE medium (Figure 2; Supplementary 
Figure S1). MK801 pre-treatment had no effect on dendrite lengths (Figure 2a), TH+ process lengths 
(Figure 2b) or GluN1 subunit levels (Figure 2c) in cultures exposed to healthy medium. In contrast to 
non-pre-treated cortical cultures, which showed a shortening of dendrites following exposure to PE 
medium (Figure 1a), exposure of MK801-pre-treated cortical cultures with PE medium led to a non-
significant increase in dendrite lengths (Figure 2a). This increase was still observed when cortical 
cultures were incubated with PE medium from preeclamptic explants that had been treated with 
MitoQ-NPs (Figure 2a). While incubation of non-pre-treated cortical cultures with PE medium led to 
a reduction in TH+ process lengths (Figure 1b), exposure of MK801-pre-treated cultures to PE 
medium, with or without MitoQ-NP treatment, did not affect TH+ process lengths (Figure 2b). In 
contrast, as observed in non-pre-treated cultures (Figure 1c), levels of GluN1 subunits were 
significantly reduced when MK801-pre-treated cultures were exposed to PE medium compared to 
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healthy medium (Figure 2c). Application of MitoQ-NPs prevented this reduction in GluN1 intensity 
in cultures exposed to PE medium (Figure 2c). To summarize, pre-treatment of cortical cultures with a 
glutamate receptor inhibitor prevented the effects of PE medium on process lengths but not on GluN1 
levels. 
 
Indirect exposure of neuron-only cultures via astrocytes replicated effects of direct exposure of 
mixed cultures to PE medium 
A recent study suggested that systemically injected lipopolysaccharide can alter the hippocampal 
cytokine microenvironment by interacting with astrocytes at the blood-brain barrier rather than 
passing through to affect the hippocampus directly (30). Therefore, the potential role of astrocytes in 
mediating the damaging effects of PE medium on neurons was explored. First, we investigated if 
astrocytes needed to be present in order for PE medium application to affect neurons in cortical 
cultures. To achieve this, neuron-only cultures that did not contain any astrocytes or other glia were 
exposed to PE medium (Figure 3a-c; Supplementary Figure S2). In contrast to mixed cultures, where 
dendrite shortening was observed following application of PE medium (Figure 1a), in neuron-only 
cultures PE medium had no effect on dendrite lengths (Figure 3a). PE medium collected following 
treatment with blank-NPs or MitoQ-NPs did not alter dendrite lengths of neuron-only cultures (Figure 
3a). While incubation of mixed cultures with PE medium led to a shortening of TH+ processes (Figure 
1b), application of PE medium to neuron-only cultures did not affect TH+ process lengths (Figure 3b). 
PE medium from blank-NP or MitoQ-NP-treated explants also did not affect TH+ process lengths in 
neuron-only cultures (Figure 3b). Compared to mixed cultures, where incubation with PE medium led 
to a reduction of GluN1 levels (Figure 1c), in neuron-only cultures levels of GluN1 subunits were not 
significantly different between neurons exposed to healthy medium or PE medium from untreated or 
NP-treated explants (Figure 3c). However, levels of GluN1 were significantly lower following 
MitoQ-NP treatment compared to blank-NP treatment (Figure 3c). Taken together, the changes in 
process lengths and levels of glutamate receptor subunits observed in mixed cortical cultures, 
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following exposure to PE medium, were not replicated in neuron-only cultures, suggesting that the 
presence of non-neuronal cells was indeed required for PE medium to affect neurons in culture. 
We next queried if astrocytes mediated the effects of PE medium on neurons via release of signalling 
molecules. Astrocyte-only cultures, devoid of neurons, were exposed to PE medium for 24 h to collect 
conditioned medium (PE-astrocytes medium). PE-astrocyte medium was then applied to neuron-only 
cultures to assess if this replicated the effects of direct application of PE medium to mixed cortical 
cultures (Figure 3d-f; Supplementary Figure S2). As observed after exposure of mixed cultures to PE 
medium directly (Figure 1a), dendrite lengths were significantly reduced in neuron-only cultures 
following exposure to PE-astrocyte medium (Figure 3d). Treatment of the preeclamptic explants with 
MitoQ-NPs did not ameliorate this effect. In line with the observed effects of PE medium on mixed 
cortical cultures (Figure 1b), TH+ process lengths in neuron-only cultures were also significantly 
reduced following exposure to PE-astrocyte medium (Figure 3e). This reduction was slightly less 
pronounced when preeclamptic explants were treated with MitoQ-NPs. Like mixed cultures exposed 
to PE medium directly (Figure 1c), neuron-only cultures showed significantly decreased GluN1 
subunit levels following exposure to PE-astrocyte medium, independent of whether preeclamptic 
explants had been treated with MitoQ-NPs or not (Figure 3f). These results indicate that signalling via 
astrocytes is required for neurons to be affected by PE medium. 
Based on the results described above, functioning glutamate receptors appear to be required for some 
of the observed effects of PE medium on neurons. Therefore, we investigated if glutamate signalling 
from astrocytes to neurons may be involved in mediating the effects of PE medium on neurons. When 
glutamate signalling in neuron-only cultures was inhibited by MK801, exposure to PE-astrocyte 
medium still significantly reduced dendrite lengths but to a lesser extent than without MK801 pre-
treatment. MitoQ-NP application did not alter dendrite lengths following MK801 pre-treatment 
(Figure 3d). TH+ process lengths were significantly increased following exposure to healthy astrocyte 
medium and application of PE-astrocyte medium led to a significant additional increase in process 
lengths, when neuron-only cultures were pre-treated with MK801. These effects were prevented by 
MitoQ-NP treatment of the placental tissue (Figure 3e). Inhibition of glutamate receptors in neuron-
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only cultures by MK801 pre-treatment prevented the effect of PE-astrocyte medium on GluN1 levels 
in neuron-only cultures. MitoQ-NP treatment had no effect on GluN1 levels in pre-treated cultures. It 
appears that glutamate signalling from astrocytes to neurons may well be one of the underlying 
mechanisms mediating the effects of PE medium on neurons. 
 
Indirect exposure to astrocyte-only cultures via neurons partially replicated effects of direct 
exposure of mixed cultures to PE medium 
We further investigated if signalling in the opposite direction, from neurons to astrocytes, could have 
an additional role in mediating the effects of PE medium on cortical cultures. As above, we first 
assessed if the presence of neurons was required for PE medium to cause changes in astrocytes. PE 
medium was applied directly to astrocyte-only cultures that did not contain any neurons (Figure 4a-d). 
In contrast to mixed cultures, where increases in astrocyte cell count and process length were 
observed following exposure to PE medium (Figure 1g,h), astrocyte-only cultures did not show any 
changes in astrocyte cell count (Figure 4a) or process length (Figure 4b) after application of PE 
medium. Exposure of astrocyte-only cultures to healthy or PE media conditioned by blank-NP or 
MitoQ-NP-treated explants did not affect cell count or process lengths. Levels of glutamate receptor 
subunits GluN1 (Figure 4c) and GluNγα (Figure 4d) were unaffected in astrocyte-only cultures 
treated with PE medium from untreated or MitoQ-NP-treated explants. To summarise, exposure of 
astrocyte-only cultures to PE medium did not reproduce the effects on astrocytes observed in mixed 
cultures exposed to PE medium, suggesting that the presence of neurons may be required for PE 
medium to exert its effects on astrocytes. 
To investigate if signalling from neurons to astrocytes plays a role in mediating the effects of PE 
medium on astrocytes, astrocyte-only cultures were exposed to culture medium conditioned by 
neuron-only cultures that had been incubated with PE medium (PE-neuron medium) (Figure 4e,f; 
Supplementary Figure S3). In contrast to mixed cortical cultures that showed an increase in astrocyte 
count following direct exposure to PE medium (Figure 1g), astrocyte-only cultures incubated with 
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PE-neuron medium had significantly reduced numbers of astrocytes (Figure 4e). Prior MitoQ-NP 
treatment of preeclamptic explants did not ameliorate this effect. As was observed in mixed cultures 
following exposure to PE medium, process lengths of astrocyte-only cultures were significantly 
increased after incubation with PE-neuron medium (Figure 4f). MitoQ-NP treatment did not affect 
astrocyte process length. Thus, the observed increase in astrocyte process length following application 
of PE medium to cortical cultures, may involve signalling from neurons to astrocytes.  
Taken together, the results suggest that the presence of neurons may be required for PE medium to 
exert its effect on astrocyte process length but not astrocyte number. 
 
Altered microRNA secretion profile from PE explants 
The above results suggest that PE medium may contain factors that damage neurons and astrocytes in 
culture. Any attempt to identify with certainty the factors released from the placenta that may affect 
cortical cultures is outside the scope of this study. Instead, we investigated if the content of the PE 
medium is altered compared to medium conditioned by healthy placentae, focussing on two relevant 
classes of molecules. 
Firstly, the results thus far implicated glutamate signalling in mediating the damaging effects of PE 
medium on neurons. This glutamate signalling may occur within cortical cultures (i.e. from astrocytes 
to neurons) or may originate directly from the placenta. Glutamate and other amino acids play an 
important role in foetal development and growth (31). Therefore, we investigated if PE medium might 
affect cortical cultures through altered levels of amino acids compared to healthy medium. 
Biochemical analysis of proteinogenic amino acids revealed no significant differences in total or 
individual levels of amino acids between PE medium and healthy medium (Figure 5a, Table 1), 
suggesting that altered secretion of amino acids from the preeclamptic placenta is not a mechanism by 
which PE medium affects cortical cells. 
Secondly, we analysed levels of microRNAs, post-transcriptional regulators with relevance to 
neurodevelopment (32) and preeclampsia (33). In a previous study, we observed differential secretion 
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of microRNAs from the rodent placenta in response to placental oxidative stress (28). Therefore, we 
hypothesised that microRNA secretion from the preeclamptic placenta might also be altered. A 
NanoString platform analysis revealed 60 microRNAs with significantly different abundance in PE 
medium compared to healthy medium (p < 0.05; Figure 5b). Predicted targets of the significant 
microRNAs are listed in Supplementary Table S1. Predicted targets were significantly enriched for 
biological processes linked to nervous system development (Table 2) and for genes associated with 
the brain (p = 7.30E-25) and placenta (p = 2.80E-12). Pathways enriched among the predicted targets 
of significant microRNAs included several signalling pathways as well as pathways with specific 
relevance to neurons, such as axon guidance (Table 3). MitoQ-NP treatment of the preeclamptic 
explants partially prevented the changes in microRNA abundance (Figure 5b). Specifically, seven of 
the microRNAs found to be differentially abundant in PE medium were also significantly altered in 
their abundance following MitoQ-NP, but not blank-NP, treatment and levels were partially returned 
to control levels (Table 4). 
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Discussion 
Conditioned medium from preeclamptic placentae affects cortical cultures 
The placenta is thought to play a key role in foetal programming of neurological disorders yet the 
process of how the placenta can affect neurodevelopment as a result of pregnancy complications 
remains poorly understood (3). The present study investigated if secreted molecules from the diseased 
placenta could affect neurons and astrocytes in vitro by exposing cortical cultures to culture medium 
conditioned by preeclamptic placentae. Exposure of cortical cells to PE medium replicated some of 
the core pathological changes observed in diseases associated with preeclampsia, such as 
schizophrenia (7, 9) and autism spectrum disorders (10). Recent studies have implicated neural circuit 
dysfunction in the aetiology of neurodevelopmental disorders (34), including a potential imbalance of 
excitatory and inhibitory inputs (35). In cortical cultures exposed to PE medium, we observed reduced 
levels of GluN1 subunits and increased levels of GABA Aα1, while levels of subunits GluNγα and 
GABA B1 were unaffected. Dysregulation of NMDA receptors (36-39) and GABA receptors (40) is 
hypothesised to represent a key contributor to schizophrenia aetiology and has been observed in post-
mortem brain tissue of patients with schizophrenia or autism, as well as in animal models. The subunit 
composition of NMDA receptors changes during development (41-45). Essential subunit GluN1 
forms heteromeric complexes with various combinations of regulatory subunits, consisting of 
GluN2α-δ and GluN3α/ȕ. These modulatory subunits define the NMDA receptor properties, including 
calcium permeability (46), induction of synaptic plasticity (47, 48) and decay kinetics (44, 49). A 
developmental switch has been observed in early postnatal development from GluN2α to GluN2ȕ (41-
44) as well as from GluN3α to GluN3ȕ (45, 46), leading to altered NMDA characteristics. While we 
might hypothesise that the observed reduction in GluN1 subunit levels in cortical cultures, following 
application of PE medium, correlates with a reduction of total NMDA receptor levels, a further 
exploration of GluN2 and GluN3 subunit levels would provide insight into potential modulatory 
effects of PE on NMDA receptors that may impact on their function and thereby contribute to altered 
neurodevelopment. Subunit composition is also critical for GABA A receptors. These receptors are 
thought to play an important role in neuronal proliferation, migration and synapse formation during 
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development (50, 51). They can be located at the synapse or extrasynaptically, where they generate 
phasic or tonic inhibition, respectively (52, 53). As phasic and tonic GABA A receptors tend to differ 
in their compositions of α, ȕ, Ȗ/δ subunits (52, 53), electrophysiological analysis of the effects of PE 
conditioned medium on cortical cultures would be of interest in order to delineate the changes in 
different GABA A receptor subunits and the concomitant effects on phasic versus tonic inhibition.  
Further observations in cortical cultures exposed to PE medium were reductions in dendrite lengths as 
well as a shortening of TH+ process lengths. In fact, cortical dendrite dysgenesis (36, 54) has been 
observed in temporal, frontal and occipital cortices of autism and schizophrenia patients, along with 
changes in the dopamine system (37, 55). Lastly, our observation that astrocyte number and process 
lengths were reduced, is in agreement with the hypothesis that altered astrocyte number or function 
may represent critical changes in autism and schizophrenia brains (56-58). 
The finding that application of PE medium, presumably containing molecules released from the 
placenta, produced changes in cortical cultures similar to those observed in brains of patients with 
relevant neurodevelopmental disorders, points towards a role of secreted placental factors in 
neurodevelopmental disease. 
As oxidative stress in the placenta has been strongly implicated in preeclampsia (15-22), we 
investigated the possible role of placental oxidative stress in mediating the release of placental factors 
that damage cortical cells. Treatment of preeclamptic placental explants with nanoparticle-bound 
MitoQ, an antioxidant that is specifically targeted to mitochondria (59) and that has previously been 
shown to reduce oxidative stress in the placenta in vivo (28), prevented all neuron-related effects of 
the PE medium but did not significantly affect astrocyte number or astrocyte process lengths. While 
the effects of MitoQ-NP treatment on oxidative stress in the preeclamptic placenta need to be further 
characterised – including the testing of different doses - the presented results suggest that placental 
oxidative stress could have a mechanistic role in the observed neuronal changes.  
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Signalling between astrocytes and neurons is required for the effects of PE medium on cortical 
cultures 
While the data suggests that as yet unidentified molecules from the preeclamptic placenta could affect 
cortical cells in culture, their mechanism of action is unknown. To investigate the potential 
involvement of astrocytes in mediating the effects of PE medium on neurons, we incubated neuron-
only cultures, without the presence of astrocytes, with PE medium. We observed none of the effects 
on dendrite lengths, glutamate or GABA receptor levels that were seen when PE medium was applied 
to mixed cultures that contained both neurons and astrocytes. Conversely, incubation of astrocyte-
only cultures with PE medium did not replicate the effects seen following PE medium application to 
mixed cultures. This indicates that the presence of both astrocytes and neurons is required for PE 
medium to affect cortical cells, thus signalling between these two cell types may play an important 
role. Bidirectional cross-talk between astrocytes is clearly important during neurodevelopment. 
Astrocytes are involved in neuronal migration and survival, neurite extension and synapse maturation, 
thereby supporting correct development of neural circuits (60). Conversely, the presence of neurons 
induces typical stellate morphology in astrocytes and astrocytic gene expression may be regulated by 
neuronal activity (61). Furthermore, astrocytes within the blood-brain barrier have been shown to 
mediate signalling of circulating factors, such as lipopolysaccharide, to neurons, without these factors 
passing through the blood-brain barrier (Hasegawa-Ishii 2016). 
Exposure of astrocyte-only cultures to PE medium and subsequent application of this conditioned 
medium to neuron-only cultures reproduced the effects of direct PE medium application to mixed 
cultures. Furthermore, exposure of astrocyte-only cultures to medium conditioned by neuron-only 
cultures that had been exposed to PE medium, replicated the effect on astrocyte process length but not 
astrocyte number. These findings further support the hypothesis that bidirectional communication 
between astrocytes and neurons plays a role in mediating the effects of PE medium on cortical cells. 
MitoQ-NP treatment of preeclamptic placentae did not rescue any of the observed effects of indirect 
exposure of cortical cells to PE medium via neurons or astrocytes. This stands in contrast to the 
preventative effect of MitoQ-NP treatment that was observed when PE medium was applied to mixed 
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cultures directly. While the reason for this observation remains unknown, it is likely that the 
mechanism by which MitoQ-NP treatment may prevent harmful secretion of molecules from the 
preeclamptic placenta is not as simple as reversing the secretion profile of the placenta back to a 
“healthy” profile. The preeclamptic placenta may release “damaging” factors that cause abnormalities 
in neurons and astrocytes. In contrast, following MitoQ-NP treatment, the placenta may alter its 
secretions to send out “supportive” signals. It is possible that the “supportive” signal from the 
placenta following MitoQ-NP application has no effect on astrocyte-only cultures or on astrocyte 
signalling to neurons. Indeed, as described above, MitoQ-NP treatment had no effect on astrocytic 
abnormalities following direct application of PE medium to cortical cultures. Therefore, this 
“supportive” signal acts either on neurons directly (which is only possible when applied directly to 
mixed cortical cultures) or on other, non-astrocytic glial cells only present in the mixed cultures. 
Indeed, microglial cells play a critical role in the developing brain, are affected in many neurological 
disorders and microglial priming, the disruption of microglia due to prenatal insults, can increase the 
vulnerability to psychiatric disorders in later life (62). Microglia may therefore also be affected by PE 
medium and/or MitoQ-NP treatment. 
To conclude, the results suggest that astrocyte-neuron signalling is required for mediating most (but 
not all) effects of PE medium on cortical cells.  
 
Glutamate signalling within cortical cultures may mediate the effects of PE medium on neurons 
Inhibition of glutamate receptors in mixed cortical cultures rescued the effects of PE medium on 
neuronal process lengths, suggesting that glutamate may mediate some the effects of PE medium on 
cortical cultures. As the major excitatory neurotransmitter in the brain, imbalance in glutamate 
signalling is a hallmark of complex neurological disorders, including schizophrenia and autism (36-
39). Bidirectional signalling via glutamate between neurons and astrocytes plays an important role in 
synaptic function, as astrocytes can modulate synaptic transmission via glutamate release at the 
tripartite synapse (63), glutamate clearance from synaptic cleft (64-66) and control of glutamate 
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diffusion in the extracellular space (67). As application of PE medium caused changes in astrocyte 
number, altered management of extracellular glutamate by astrocytes could potentially play a role in 
mediating the effects of PE medium on neurons.  
Glutamate receptor inhibition in neuron-only cultures exposed to astrocyte-PE medium, rescued 
neuronal process lengths and GluN1 levels. In fact, process lengths were increased following 
application of healthy medium to neurons pre-treated with glutamate receptor inhibitor. Taken 
together with the mixed culture results, glutamate receptor inhibition has different effects, depending 
on whether glutamate signalling was inhibited in general or specifically with regard to astrocyte-to-
neuron signalling. This suggests that other factors are involved in mediating the effects of PE medium 
on neurons, in addition to glutamate. Previous studies have implicated other amino acids, 
neurotransmitters (or gliotransmitters), neuropeptides, cytokines and small signalling molecules (NO, 
CO) in the bidirectional neuron-astrocyte crosstalk (68, 69). 
 
microRNAs as candidate placental signalling molecules 
In the present study we observed an altered microRNA secretion profile from the preeclamptic 
placenta compared to healthy controls. Predicted targets of these differentially secreted microRNAs 
were enriched for nervous system development, brain and placenta. MitoQ-NP application partially 
ameliorated the altered secretion profile, with seven microRNAs being affected both by disease status 
and treatment. This observation correlates with the suggestion from the cortical culture data that 
MitoQ-NP application in this model does not necessarily return the placental secretion profile to 
“healthy” levels. Instead, it appears that MitoQ-NP treatment alters the secretion levels of selected 
microRNAs, together with other active factors, to an extent that is sufficient to prevent the damaging 
effects of PE medium on neurons. 
microRNAs have been shown to be released from a variety of cells into the blood and other body 
fluids and to be taken up by recipient cells, including neurons and astrocytes, where they are able to 
exert their functional role of post-transcriptional regulation of gene expression (70). Other glial cells 
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not investigated in the present study, such as microglia, have also been shown to take up extracellular 
microRNAs (71). Thus, their function could also be affected by microRNAs released from a 
preeclamptic placenta and could contribute to associated neurodevelopmental dysfunction. In addition 
to their role in neurodevelopment (32) and neuropsychiatric disorders (32, 72), microRNAs are 
released from the placenta within exosomes into the maternal blood. They are thought to provide a 
feedback mechanism to the maternal system and have been assessed as potential biomarkers for 
preeclampsia (73-75), gestational hypertension (76) and foetal growth (77), among others. We have 
recently shown in a model of gestational hypoxia that the hypoxic placenta differentially secretes 
microRNAs while the microRNA profile in the foetal blood is also altered (28). Levels of these 
differentially abundant microRNAs negatively correlated with mRNA levels of their predicted targets 
in the foetal brain. Moreover, predicted targets of the differentially secreted microRNAs were 
enriched for schizophrenia-linked copy number variants, pointing towards a potential role of 
microRNAs in mediating the effects of a diseased placenta on the foetal brain (28). If placental 
microRNAs secreted into the foetal circulation reach and enter the brain, is so far unknown. It has 
been shown, however, that exosomes carrying RNA molecules are able to cross the blood-brain 
barrier (78). Therefore, it is possible that microRNAs released from the placenta may influence 
developmental changes in the brain.  
Much of the literature has focussed on factors released from the placenta towards the maternal, rather 
than the foetal, circulation (79). And indeed, many proteins that are produced by the placenta are 
detected in much higher levels in the maternal blood compared to cord blood, suggesting that the 
placenta preferentially secretes these factors towards the maternal circulation (80). However, other 
factors have recently been identified that are released from the placenta towards the foetus and taken 
up into the foetal brain, where they regulate neurodevelopmental processes, such as serotonin (81). 
This response was altered following exposure to noxious stimuli including immuno-stimulation (82). 
Clearly, there is a need for a better understanding of placental factors that are released towards into 
the foetal circulation and affect foetal development. 
17 
While the differential release of microRNAs from the PE placenta needs to be independently 
validated, as well as their functional role confirmed and understood on a mechanistic level, the present 
results demonstrated that microRNA secretion from the preeclamptic placenta is perturbed and could 
thus constitute a potential communication mechanism between the placenta and foetal cortical cells. It 
is likely that any such microRNA involvement acts in concert with other secreted factors, such as 
proteins and hormones, as well as molecules that cross the placenta from the maternal milieu. 
Comprehensive characterisation of the conditioned medium will be required to fully identify the range 
of factors released from the placenta that may influence foetal development as a result of 
preeclampsia. 
 
Conclusion 
In the present study, we demonstrated that secretions from the PE placenta affected neurons and 
astrocytes in culture (Figure 6), suggesting that placental signalling to the foetal brain, potentially 
induced by oxidative stress in the placenta, may be important for neurodevelopment.  
Analysis of what the PE placenta secretes could also provide further insight into the factors that the 
placenta releases into the maternal circulation, in PE. Previous studies have identified a reduction in 
small signalling molecules (H2S, CO, NO) and increases in pro-inflammatory mediators, procoagulant 
factors and in some cases anti-angiogenic factors released from the PE placenta (79). Furthermore, a 
variety of vesicles are secreted from the syncytiotrophoblast and the composition of their cargo of 
proteins, RNA and microRNAs is thought to be altered in PE (83, 84). Systemic effects of these 
altered circulating factors may contribute to the maternal syndrome in PE and to the possible onset of 
seizures, termed eclampsia. If placental factors released into the maternal circulation could cross the 
blood-brain barrier, which is thought to be more permeable in PE (85), cause neurological changes in 
the maternal brain and thereby increase the brain’s vulnerability to seizures is unknown. It is of 
relevance, however, that magnesium sulphate, which is used clinically for prevention of eclamptic 
seizures, is an NMDA receptor antagonist (86). As placental pathology is central to the development 
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of the maternal syndrome in PE, treatment of the placenta with an antioxidant might not only lead to a 
change in placental molecules released towards the foetus, but also towards the mother. We have 
previously shown in a rat model of hypoxia during pregnancy, that treatment of the mother with 
MitoQ-NP, which rescued neurodevelopment in the foetus, also reduced hypoxia-induced oxidative 
stress in the maternal brain and liver (28). No obvious side effects on the mother were observed, 
however, the effects of MitoQ-NP treatment on the mother require comprehensive characterisation. 
Future studies will show if treatment of the placenta may also have beneficial implications for the 
mother. 
Further exploration of the mechanistic link between the release of molecules from the placenta and 
changes in cortical cells will provide a deeper understanding behind the foetal origin of 
neurodevelopmental diseases, as well as open up opportunities for treating of the placenta with 
targeted drugs to reduce the risk of neurodevelopmental disease in offspring of complicated 
pregnancies. 
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Materials and methods 
Experimental design 
Explants from preeclamptic or healthy human placentae were cultured for 24 h with addition of blank-
NPs, MitoQ-NPs or without NPs. The conditioned medium was added to mixed cortical cultures, 
astrocyte-only cultures or neuron-only cultures for 24 h (Figure 7A), after which cultures were 
assessed by immunohistochemistry, as described below. In a second step, conditioned medium was 
collected from astrocyte-only cultures and added to neuron-only cultures for 24 h (Figure 7B). 
Alternatively, conditioned medium was obtained from neuron-only cultures and applied to astrocyte-
only cultures (Figure 7C). This approach enabled investigation of the roles of astrocytes and neurons 
in mediating the effects of placenta-conditioned medium on cortical cultures. 
 
Tissue collection 
De-identified human tissue was obtained from Southmead Hospital (Bristol, UK) with patients’ 
written informed consent and ethical approval by the NHS Health Research Authority. Mild, moderate 
or severe preeclampsia was diagnosed based on NICE clinical guideline 107 (Table 5). Preeclamptic 
placentae were delivered by induction or caesarean section. Control samples were obtained from non-
diseased women following elective term caesarean delivery. Within 30 min of delivery, explants of 
villous tissue (~0.5 cm3) were dissected from the placenta midway between chorionic and basal plates. 
 
Conditioned medium 
MitoQ (gift from Dr Michael Murphy, University of Cambridge) (59) and Ȗ-PGA-Phe nanoparticles 
(gift from Dr. Mitsuru Akashi, Osaka University) (87) were combined to produce MitoQ-NPs (28). 
Following addition of 0.5 μM MitoQ-NPs or equivalent volume of blank-NPs, placental explants were 
incubated for 24 h in Gibco Neurobasal media with 1x B-27 Supplement, 1x antibiotic-antimycotic 
(Thermo Fisher Scientific) and 2 mM L-glutamine (Sigma-Aldrich). 
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Conditioned medium samples were randomly selected for analysis (Table 3). Amino acids were 
measured as previously described (28, 29). Total RNA was isolated from conditioned medium using 
the miRNeasy Mini Kit (Qiagen, Germany) and levels of individual microRNAs were analysed with 
the nCounter Human v2 miRNA Expression Assay (NanoString Technologies, USA). Differential 
abundance of microRNAs was analysed as previously described (28). Briefly, unwanted variation was 
removed with RUVSeq (88) and differentially abundant microRNAs were then predicted using edgeR 
(89). Predicted targets of differentially abundant microRNAs were downloaded from 
TargetScanHuman 7.2 (90) with a context++ score threshold of -0.2. Enrichment analysis of predicted 
microRNA targets was performed using the GO-slim feature in PANTHER 11.0 (91, 92) as well as 
the UP_TISSUE and KEGG pathway features in DAVID 6.8 (93, 94). Generated data files have been 
deposited in NCBI’s Gene Expression Omnibus (95) (accession number GSE110786). 
 
Cortical cultures 
Mixed, astrocyte-only and neuron-only cortical cultures were prepared from dissociated rat E18 
cortical tissue (29). The effect of glutamate receptor inhibition was investigated by adding 10 μM 
MK801 to the cultures 4 h before incubation with conditioned media. Immunocytochemical 
assessment was performed as described previously (28) using antibodies against MAP2 (Synaptic 
Systems 188004; 1:2000), GFAP (CST 3670; 1:1000), tyrosine hydroxylase (abcam ab112; 1:500), 
GluN1 (Millipore Ab9864; 1:β00), GluNγα (Millipore 07-γ56; 1:β00), GABA Aα1 (abcam abγγβ99; 
1:250) and GABA B1 (abcam ab55051; 1:250).  
 
 
 
Statistics 
Two-way ANOVA was performed in Prism 6.0 (GraphPad, USA) or SPSS 21.0 (IBM Corp., USA) 
with post-hoc analysis using Bonferroni correction or Tukey’s test for multiple comparisons. 
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Figures and legends 
 
Figure 1 – Effects of healthy and PE medium on mixed cortical cultures. Mixed cortical cultures 
were exposed to medium conditioned by healthy (n = 6) or preeclamptic (n = 6) placental explants 
that had been pre-treated with no NPs, blank-NPs or MitoQ-NPs. Following a 24 h exposure, cortical 
cultures were assessed for neuronal dendrite lengths (a), process lengths of TH+ cells (b), levels of 
glutamate receptor subunits GluN1 (c) and GluNγα (d), levels of GABA receptor subunits GABA 
Aα1 (e) and GABA B1 (f), along with astrocyte count (g) and astrocyte process lengths (h). Data are 
presented as means + s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 2 – Role of glutamate inhibition in mediating effects of PE medium on mixed cortical 
cultures. Mixed cortical cultures were incubated with NMDA receptor antagonist MK801 prior to 
exposure to culture medium conditioned by healthy (n = 6) or preeclamptic (n = 6) placental explants 
that had been treated with no NPs or with MitoQ-NPs. Lengths of neuronal dendrites (a), lengths of 
TH+ cell processes (b) and levels of glutamate receptor subunit GluN1 (c) were measured in the 
cortical cultures (data are presented as means + s.e.m. ***p < 0.001). 
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Figure 3 – Role of astrocytes in mediating effects of PE medium on neurons. a-c. Neuron-only 
cortical cultures were exposed directly to medium conditioned by healthy or preeclamptic placental 
explants, which had been pre-treated with no NPs, blank-NPs or MitoQ-NPs. d-f. In a second 
experiment, neuron-only cultures were exposed to medium collected from astrocyte-only cortical 
cultures, which had previously been exposed to the placenta conditioned medium, and some neuronal 
cultures were additionally pre-treated with NMDA receptor antagonist MK801. Neuronal dendrite 
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lengths (a,d), TH+ process lengths (b,e) and glutamate receptor subunit GluN1 levels (c,f) were 
measured (data are presented as means + s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001). 
 
Figure 4 – Role of neurons in mediating effects of PE medium on astrocytes. a,b. Astrocyte-only 
cortical cultures were exposed directly to medium conditioned by healthy or preeclamptic placental 
explants, which had been pre-treated with no NPs, blank-NPs or MitoQ-NPs. c-f. In a second 
experiment, astrocyte-only cultures were exposed to medium collected from neuron-only cortical 
cultures, which had previously been exposed to the placenta conditioned medium. Astrocyte cultures 
were assessed with regard to cell count (a,e), process lengths (b,f) along with levels of glutamate 
receptor subunits GluN1 (c) and GluNγα (d) (data are presented as means + s.e.m. **p < 0.01, ***p < 
0.001). 
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Figure 5 – Characterisation of PE conditioned medium. a. Total levels of proteinogenic amino 
acids (µmol/l ± s.e.m.) were measured in culture medium conditioned by healthy (n = 3) or 
preeclamptic (n = 3) placental explants, following pre-treatment with no NPs, blank-NPs or MitoQ-
NPs. b. Log 2 fold change values are shown for those microRNAs that were significantly altered in 
PE medium (n = 4) compared to healthy medium (n = 4) (blue). Log fold changes of those same 
microRNAs in medium conditioned by preeclamptic placental explants treated with MitoQ-NPs (n = 
3), compared to untreated PE medium, are shown in orange. 
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Figure 6 – Overview of potential mechanistic effects of PE medium on cortical cultures. Secreted 
molecules from the preeclamptic placenta, including potentially microRNAs, may have direct effects 
on neurons and astrocytes. Some of the effects of PE medium on cortical cultures may also be indirect 
via glutamate secretion from astrocytes or by secretion of unknown factors from neurons. 
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Figure 7 – Overview of experimental setup. Culture medium conditioned by healthy or 
preeclamptic placental explants, following exposure to no NPs, blank-NPs or MitoQ-NPs, was applied 
to mixed cortical cultures, astrocyte-only cortical cultures or neuron-only cortical cultures (A). To 
establish the role of astrocytes in mediating the effects of placenta-conditioned medium on cortical 
cultures, culture medium from the exposed astrocyte-only cultures was applied to neuron-only 
cultures (B); in order to investigate the role of neurons in mediating the effects of placenta condition 
medium on cortical cultures, culture medium from neuron-only cultures that had been exposed to 
placenta-conditioned medium was applied to astrocyte-only cultures (C). 
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Tables and legends 
Table 1 – Amino acid concentration in μmol/L (±s.e.m.) in medium conditioned by healthy (n = 3) 
or preeclamptic placentas (n = 3), after exposure to no NPs, blank-NPs or MitoQ-NPs.  
 Healthy PE 
Amino 
acid No NP Blank-NP MitoQ-NP No NP Blank-NP MitoQ-NP 
Ala 79.27 (45.02) 
90.93 
(64.43) 
54.77 
(24.70) 
79.70 
(52.22) 
64.07 
(42.47) 
251.0 
(228.84) 
Arg 357.0 (5.483) 
335.7 
(33.79) 
331.8 
(19.46) 
336.6 
(6.552) 
332.7 
(17.84) 
371.1 
(26.71) 
Asn 16.63 (16.63) 
21.33 
(21.33) 
7.833 
(7.833) 
15.07 
(15.07) 
11.70 
(11.70) 
94.13 
(94.13) 
Asp 0 (0) 
0 
(0) 
0 
(0) 
0 
(0) 
0 
(0) 
67.17 
(67.17) 
Cys 58.63 (7.636) 
58.10 
(2.001) 
62.60 
(7.614) 
67.57 
(4.927) 
69.83 
(4.190) 
66.27 
(4.983) 
Gln 1509 (396.8) 
1411 
(275.0) 
1358 
(318.2) 
1293 
(436.2) 
1273 
(442.3) 
1464 
(477.7) 
Glu 64.73 (53.55) 
67.90 
(67.90) 
36.10 
(30.62) 
41.00 
(24.97) 
62.97 
(50.80) 
201.4 
(188.5) 
Gly 409.4 (34.20) 
384.3 
(51.72) 
356.8 
(24.70) 
398.9 
(30.74) 
393.3 
(52.11) 
585.4 
(223.0) 
His 153.3 (12.70) 
143.4 
(21.24) 
142.9 
(15.69) 
127.8 
(7.503) 
139.2 
(10.12) 
185.2 
(59.89) 
Ile 702.4 (35.45) 
629.6 
(17.69) 
647.5 
(28.17) 
683.4 
(48.12) 
682.9 
(46.88) 
770.0 
(59.13) 
Leu 554.4 (192.9) 
674.5 
(23.68) 
671.0 
(24.70) 
725.4 
(30.02) 
720.2 
(53.58) 
908.5 
(177.8) 
Lys 736.7 (17.91) 
674.5 
(36.12) 
675.6 
(26.43) 
726.3 
(15.76) 
721.9 
(61.11) 
890.9 
(170.8) 
Met 171.6 (7.270) 
154.1 
(4.206) 
152.5 
(7.878) 
162.5 
(10.52) 
175.0 
(13.83) 
208.4 
(40.77) 
Phe 377.8 (14.26) 
344.5 
(15.59) 
346.3 
(14.85) 
386.8 
(9.103) 
390.2 
(33.93) 
467.3 
(79.52) 
Pro 86.00 (17.56) 
87.20 
(34.33) 
72.50 
(12.85) 
146.1 
(66.25) 
100.4 
(33.79) 
252.7 
(188.6) 
Ser 377.4 (9.481) 
346.9 
(23.40) 
342.9 
(13.37) 
369.1 
(13.16) 
358.1 
(31.58) 
514.3 
(151.0) 
Thr 740.6 (23.73) 
671.67 
(27.48) 
679.6 
(27.09) 
711.6 
(27.48) 
716.3 
(53.71) 
829.0 
(106.1) 
Trp 0 (0) 
0 
(0) 
0 
(0) 
0 
(0) 
0 
(0) 
23.73 
(23.73) 
Tyr 366.2 (10.53) 
330.2 
(14.00) 
336.4 
(13.60) 
364.8 
(12.40) 
355.7 
(26.76) 
433.0 
(60.29) 
Val 733.8 (27.62) 
673.4 
(23.32) 
671.8 
(26.17) 
734.27 
(27.35) 
741.7 
(56.19) 
893.6 
(153.5) 
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Table 2 – Enriched biological processes. Results of gene ontology analysis of predicted targets of 
differentially abundant microRNAs in PE placenta conditioned medium compared to healthy placental 
conditioned medium are listed. p values have been corrected for multiple comparisons using FDR.  
Biological process Count Fold enrichment p value 
sensory perception of chemical stimulus 3 < 0.2 3.20E-23 
developmental process 468 1.53 1.99E-17 
sensory perception of smell 1 < 0.2 1.17E-16 
intracellular signal transduction 262 1.67 4.44E-13 
sensory perception 40 0.38 3.47E-11 
signal transduction 518 1.37 4.18E-11 
MAPK cascade 108 2.16 1.16E-10 
cell communication 565 1.34 1.88E-10 
cell cycle 226 1.59 5.55E-09 
nervous system development 173 1.64 1.42E-07 
system development 248 1.47 5.14E-07 
cellular process 1461 1.13 8.56E-07 
death 118 1.74 3.21E-06 
cell death 118 1.74 3.21E-06 
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Table 3 – Top 15 enriched pathways. Results of KEGG pathway analysis of predicted targets of 
differentially abundant microRNAs in PE placenta conditioned medium compared to healthy placental 
conditioned medium are listed. p values have been corrected for multiple comparisons using 
Benjamini-Hochberg method.  
KEGG pathway Count Fold enrichment p value 
MAPK signalling pathway 106 2.40 1.11E-17 
Ras signalling pathway 89 2.27 5.58E-13 
Pathways in cancer 127 1.86 1.51E-11 
Neurotrophin signalling pathway 55 2.64 8.13E-11 
Rap1 signalling pathway 79 2.17 1.58E-10 
PI3K-Akt signalling pathway 112 1.87 1.89E-10 
Melanoma 37 3.00 4.36E-09 
Axon guidance 53 2.41 8.11E-09 
ErbB signalling pathway 41 2.72 1.44E-08 
FoxO signalling pathway 54 2.32 1.98E-08 
Renal cell carcinoma 33 2.93 7.95E-08 
T cell receptor signalling pathway 44 2.46 9.83E-08 
Signalling pathways regulating pluripotency of stem cells 54 2.22 9.61E-08 
Regulation of actin cytoskeleton 71 1.94 2.24E-07 
Insulin signalling pathway 52 2.17 4.19E-07 
 
  
32 
Table 4 – microRNAs significantly affected in preeclampsia and by MitoQ-NP treatment. Listed 
are those microRNAs that were found to be up or downregulated in culture medium conditioned by 
preeclamptic placental explants, compared to healthy explants, and that were also affected in the 
opposite direction by treatment of the placenta with MitoQ-NPs but not blank-NPs. 
microRNA Known relevant functions 
  
Upregulated in PE  
hsa-miR-561-5p Regulates 11ȕ-HSD1, which is highly expressed in liver, 
adipose tissue and CNS (96) 
Associated with Parkinson’s disease (97) 
hsa-miR-548ai+hsa-miR-570-5p miR-570 associated with autism (98) and congenital heart 
disease (99) 
miR-570 regulates cytochrome P450 (100) 
hsa-miR-196b-5p Associated with ectopic pregnancy (101) 
Associated with endometriosis (102) 
hsa-miR-2117 None 
hsa-miR-3065-3p None 
  
Downregulated in PE  
hsa-miR-596 None 
hsa-miR-451a Associated with type 2 diabetes (103) 
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Table 5 – Clinical data of collected preeclamptic placentae. APKD, Adult polycystic kidney 
disease; DM1, type 1 diabetes; DVT, deep vein thrombosis; IUGR, intrauterine growth restriction; 
PCR, protein-creatinine ratio; SLE, systemic lupus erythematosus. Conditioned media from the 
highlighted placentas was *applied to cortical cultures; #analysed for amino acids; $analysed for 
microRNA. 
 Gestation Parity Severity PCR IUGR Co-morbidities 
1* 35+5 0 Moderate 274 Unknown n/a 
2* 37+3 0 Moderate 361 No n/a 
3*#$ 40+8 2 Mild 204 No n/a 
4* 40+13 0 Moderate 331 No Hypothyroid 
5*$ 37 0 Severe 427 Unknown DM1 
6*$ 27+4 0 Severe 537 Yes APKD 
7*#$ 26+1 1 Severe 448 Yes 
SLE nephritis, previous 
DVT/pulmonary embolus, baby 
has metabolic disorder 
8*# 38+4 4 Severe 32 No n/a 
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